Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
24.61
+0.01 (+0.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
9
Next >
6 Analysts Assess Alkermes: What You Need To Know
July 15, 2024
Via
Benzinga
"Rule Breaker Investing" Stock Pick Review: The Big One
July 15, 2024
Looking back at 30 five-stock samplers picked from 2015 to 2021.
Via
The Motley Fool
NASDAQ:ALKS is an undervalued gem with solid fundamentals.
July 11, 2024
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
June 19, 2024
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
The Analyst Landscape: 7 Takes On Alkermes
June 17, 2024
Via
Benzinga
6 Analysts Assess Alkermes: What You Need To Know
May 23, 2024
Via
Benzinga
7 Analysts Assess Alkermes: What You Need To Know
May 02, 2024
Via
Benzinga
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
May 02, 2024
Should you consider ALKERMES PLC (NASDAQ:ALKS) for growth investing?
Via
Chartmill
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
April 10, 2024
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
In a market where value is scarce, NASDAQ:ALKS offers a refreshing opportunity with its solid fundamentals.
May 29, 2024
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
May 25, 2024
Investors should take a close look at these biotech stocks as they position themselves to provide high returns.
Via
InvestorPlace
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
May 08, 2024
ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024
May 01, 2024
ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
April 17, 2024
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
April 09, 2024
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2...
Via
Benzinga
Breaking Down Alkermes: 5 Analysts Share Their Views
April 09, 2024
Via
Benzinga
Is NASDAQ:ALKS suited for growth investing?
March 20, 2024
Is ALKERMES PLC (NASDAQ:ALKS) suited for growth investing?
Via
Chartmill
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
March 19, 2024
Via
Benzinga
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
March 27, 2024
When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
A Look Into Healthcare Sector Value Stocks
March 11, 2024
Via
Benzinga
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Via
Investor's Business Daily
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
March 05, 2024
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Exploring NASDAQ:ALKS's growth characteristics.
February 28, 2024
Why the growth investor may take a look at NASDAQ:ALKS.
Via
Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.
Via
Investor's Business Daily
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Alkermes's Earnings Outlook
February 14, 2024
Via
Benzinga
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
February 23, 2024
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
Via
Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
February 21, 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.
Via
InvestorPlace
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
February 15, 2024
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday.
Via
Investor's Business Daily
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
February 13, 2024
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.